July 22, 2014
CHICAGO (AP) - A new study suggests that adding a targeted cancer drug to standard chemotherapy helps advanced lung cancer patients live a month longer.
But the results left doctors mostly disappointed. They had been hoping for the drug Erbitux to provide a bigger benefit.
The study tested the drug in more than 1,100 people with lung cancer that had already spread widely. Average survival was just over 11 months for those given Erbitux on top of standard chemotherapy, versus just over 10 months for those on chemo alone.
The study is to be presented tomorrow at a meeting in Chicago of the American Society of Clinical Oncology.
(Copyright 2008 by The Associated Press. All Rights Reserved.)